ABVC BioPharma Financials - Benzinga

ABVC BioPharma Inc

ABVCNASDAQ

Trade with Public

Trade with Public

$0.9601

-0.0399-3.99%

At close: Sep 4, 5:00 PM EST

$1.04

0.07998.32%

After Hours: Sep 4, 9:15 AM EST

Overview News Earnings ForecastFinancialsSentiment Compare Options Stock Report

ABVC BioPharma Financials

ABVC BioPharma (ABVC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
ABVC BioPharma Q1 EPS $(0.06), Same YoY

ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.06) per share. This is unchanged from the same period last year.

Benzinga Newsdesk

PRO
Abvc Biopharma Says Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon; Reports Material Weakness In Internal Controls Over Financial Reporting For FY25

Benzinga Newsdesk

PRO
ABVC BioPharma Q3 EPS $(0.05) Down From $(0.03) YoY, Sales $795.950K Up From $389.276K YoY

ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.05) per share. This is a 66.67 percent decrease over losses of $(0.03) per share from the same period last year. The company reported $795.950 thousand in

Benzinga Newsdesk

PRO
ABVC BioPharma Q2 EPS $(0.13) Down From $(0.09) YoY

ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.13) per share. This is a 44.44 percent decrease over losses of $(0.09) per share from the same period last year.

Benzinga Newsdesk

PRO
ABVC BioPharma Determined That It Has A Material Weakness In Its Internal Controls Over Financial Reporting; Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements

Benzinga Newsdesk

PRO
ABVC BioPharma Q3 EPS $(0.02) Up From $(0.82) YoY, Sales $389.28K Up From $15.88K YoY

Benzinga Newsdesk